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The paper of Thompson et al. contributes from both a scientific and a clinical point of 
view to a timely and relevant issue, namely the potential role of the ethanol 
metabolite phosphatidylethanol (PEth) as a biomarker for assessing ethanol intake in 
autopsy cases. 
To facilitate early diagnosis and therapy of alcohol-related disorders and thus prevent 
secondary complications, questionnaires like the Alcohol Use Disorders Identification 
Test (AUDIT) (Saunders et al., 1993) together with reliable and valid biomarkers are 
useful. Clearly, biomarkers have the advantage to indicate and reflect alcohol intake, 
independent of recall bias of the interviewed subjects. Among biomarkers of ethanol 
intake, ethanol metabolites such as ethyl glucuronide (EtG) and, more recently, PEth 
have been investigated. PEth is now recommended by the German evidence- and 
consensus-based Guideline on alcohol use disorders for screening chronic alcohol 
intake at the highest level of evidence (level 1) in all settings for assessing drinking 
habits (Weinmann et al., 2016). PEth has been employed in settings such as the 
assessment of driving ability, in forensic psychiatry, in monitoring programs, and for 
identifying alcohol intake in specific risk groups, e.g., for neonatal screening of 
prenatal alcohol exposure (for review see Wurst et al., 2015). 
It should be noted that PEth is not a single molecule but a family of phospholipids 
with different fatty acids at the sn-1 and sn-2 positions (Gnann et al., 2010). Nutrition 
can influence the lipids available to be transformed into PEth homologues, and thus 
mediate the substitution of different fatty acids. 
LC-MS/MS allows PEth to be detected in blood after a single drinking episode, while 
multiple drinking on five subsequent days leads to the accumulation of PEth in blood 
(Gnann et al., 2012). In volunteers a single drinking episode to a blood alcohol 
concentration (BAC) of 1.0 g/kg (approx. 0.1 g/dL) resulted in a detection window of 3 
to 12 days (Schröck et al., 2016b). During abstinence the ratios of different PEth 
homologues change due to their differing elimination times (Gnann et al., 2014). As 
PEth seems to be formed as long as alcohol is present in the blood, and higher BAC 
levels lead to a higher formation rate, the manner of drinking (speed, frequency, 
single-drinking amounts) and the BAC reached per drinking event may play roles in 
PEth production. However, this has not yet been investigated in detail. 
No paper has so far looked at PEth degradation in vivo, nor its mechanism of 
degradation and which products are formed. Apart from phospholipase D (PL D) 
activity, PL A1, PL A2, PL B and PL C can also lead to different forms of “lyso”-PEth, 
which are currently not detected by LC-MS/MS methods. A variety of possibilities 
might explain inter-individual differences in the formation of certain PEth homologues. 
The investigated samples were autopsy cases from a brain bank with death by 
suicide or from natural causes. To establish a diagnosis, the Mini-International 
Neuropsychiatric Interview (M.I.N.I.) with DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders, American Psychiatric Association) criteria was employed. Of 
note, a differentiation between a lifetime and a current diagnosis of AUD was not 
possible with the given information. This would have been of interest for data 
interpretation. In addition to this excellent diagnostic tool, it would be beneficial in 
future studies to have information about ethanol intake over the days, weeks and 
months prior to death. Such information could have been provided by the AUDIT or 
by time-line follow back (TLFB), as used for many other studies with living persons. 
The study is based on PEth concentrations, serum blood levels, and coroner’s 
reports, reports from next of a kin, on the manner of death and circumstances with 
the differentiation of suicide and death from natural causes, with a relatively small 
number of autopsy samples, and thus should be regarded as a pilot study. 
The samples used were classified into three groups: AUD-W (with positive serum 
ethanol levels present at the time of autopsy), AUD-WO (without positive serum 
ethanol levels), and controls. Since the control group was positive for PEth, it should 
be assumed that these persons were no teetotalers, but showed at least occasional 
alcohol consumption. It is not clear if the diagnosis was lifetime or current for AUD-W 
or AUD-WO. 
Compared with other forensic autopsy case reports, no morphological characteristic 
signs for alcohol abuse, such as structural liver damage, are mentioned in the study. 
Furthermore, no analysis of other autopsy material, such as urine or hair for EtG, was 
performed to assess consumption habits prior to death. Correlations between hair 
EtG concentrations and blood PEth concentrations have recently been shown by 
Schröck et al. (2016a). 
Alcohol concentration has been determined in serum, and the complementary 
determination of EtG in serum and γ-glutamyl-transferase in serum (GGT) would 
have added aspects from different time frames of alcohol intake. 
In contrast to earlier papers on PEth in tissue samples from rats and human subjects 
(Aradottir et al., 2002, 2004), where HPLC with evaporative light scattering detection 
was used to quantify the sum of all PEth homologues, in the present paper individual 
PEth homologues were quantified by LC-MS/MS. 
Interestingly, brain tissue seems to show some differences from erythrocytes or blood 
samples in the profile of PEth homologues after ethanol consumption. This might be 
due to turnover rate, which is dependent on enzymatic activity and the presence of 
educts for PEth homologue biosynthesis across brain regions. Also, steric issues with 
the multiple unsaturated lipid moieties, or oxidative processes, might play roles. 
There are few data on the presence of PL D (Exton, 2002), which catalyzes the 
reaction of phosphatidylcholine with ethanol to form PEth (Kobayashi and Kanfer, 
1987), and no mention of the presence of other phospholipases that could influence 
PEth concentrations. The degree of unsaturation of the fatty acid moieties influences 
their stability. Post-mortem redistribution of metabolites might play a role, including in 
brain. 
It should also be mentioned that blood is still present in the brain after death, and as 
a result there might be diffusion between erythrocytes and brain cells. 
Furthermore, the possibility of continued formation of PEth in tissue in the presence 
of alcohol after death, which has been observed in blood if not stored at -80°C, might 
lead to somewhat falsely elevated PEth concentrations.  
From a technical point of view, other factors could influence the ratio of PEth 
homologues: the liquid-liquid extraction technique used with brain tissue is very 
similar to techniques used for whole blood. The paper does not mention how 
recovery and extraction efficiency were determined for brain tissue. Control samples 
containing PEth are not commercially available, and are usually only generated by 
spiking blank material with the analytes of interest. Systematic variations in extraction 
need to be compensated for. As no deuterated standard was used to determine PEth 
16:0/18:2, only 16:0/18:1, it is unclear if PEth 16:0/18:2 recovery was tested. Some 
chemical suppliers are now producing control material for the quantification of PEth 
homologues (in dried blood spots), since stability issues are a major problem. Inter-
laboratory comparability of results remains an unsolved problem, especially for tissue 
samples. 
Finally, the authors discuss possible limitations of their study, and state that “our 
results are not conclusive”. The results need to be verified by further investigations 
that include a range of markers and signs of prolonged alcohol abuse – and also by 
the evaluation of storage conditions, pre-analytical stability, and the diffusion rates of 
these highly lipophilic compounds. Studies on lipase activity in brain tissue are also 
important. 
In summary, the study adds to the increasing body of evidence for the advantages of 
PEth as biomarker of ethanol intake. Of note, a plethora of variables apart from daily 
amount of alcohol consumed that influence PEth concentrations, such as gender 
(which influences the area-under-the-curve for BAC), nutrition, and inter-individual 
differences in the activities of enzymes that form and degrade PEth homologues, 
among others, might contribute to the variation found. Additional information on 
current drinking status should be considered in future work. 
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